Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „Adtralza“
Suchtreffer
Begriffe & Kennungen
Adtralza
Eintrag öffnenAdtralza · 4.1 Therapeutic indications · 1
Eintrag öffnenAdtralza · 4.3 Contraindications · 1
Eintrag öffnenAdtralza · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenAdtralza · 4.4 Special warnings and precautions for use · 1
Eintrag öffnenAdtralza · 4.5 Interaction with other medicinal products and other forms of interaction · 1
Eintrag öffnenAdtralza · 4.5 · For information on live and live attenuated vaccines, see section 4.4.
Eintrag öffnenAdtralza · 4.5 · Immune responses to non-live vaccines were assessed in a study in which adult patients with atopic dermatitis
Eintrag öffnenAdtralza · 4.5 · Interactions with cytochrome P450
Eintrag öffnenAdtralza · 4.5 · The effects of tralokinumab on the pharmacokinetics (PK) of CYP substrates, caffeine (CYP1A2), warfarin (CYP2C
Eintrag öffnenAdtralza · 4.5 · The safety and efficacy of concurrent use of tralokinumab with live and live attenuated vaccines has not been
Eintrag öffnenAdtralza · 4.5 · Tralokinumab is not expected to undergo metabolism by hepatic enzymes or renal elimination. Clinically relevan
Eintrag öffnenAdtralza · 4.6 Fertility, pregnancy and lactation · 1
Eintrag öffnenAdtralza · 4.8 Undesirable effects · 1
Eintrag öffnenAdtralza · 4.8 · 6 The rate of conjunctivitis in the initial 16 weeks treatment period was 22.0 events/100 patient years of exp
Eintrag öffnenAdtralza · 4.8 · 7 The rate of injection site reactions in the initial 16 weeks treatment period was 51.5 events/100 patient ye
Eintrag öffnenAdtralza · 4.8 · ADA incidences in patients who received tralokinumab for up to 6 years (in phase 2/phase 3 atopic dermatitis s
Eintrag öffnenAdtralza · 4.8 · Adverse reactions observed from clinical trials and post-marketing experience are presented in Table 1 by syst
Eintrag öffnenAdtralza · 4.8 · Anti-drug-antibody (ADA) responses were not associated with any impact on tralokinumab exposure, safety, or ef
Eintrag öffnenAdtralza · 4.8 · Blood and lymphatic Common Eosinophilia system disorders Eye disorders Common Conjunctivitis allergic Uncommon
Eintrag öffnen